Read by QxMD icon Read

Lymphoma Outcomes

Hui Zou, Runying Zou, Keke Chen, Chengguang Zhu, Xin Tian, Yalan You, Xiangling He
Burkitt lymphoma is one of the most common lymphatic system cancers with poor outcome in adult patients. p53-induced apoptosis is a critical signaling for preventing tumor development. Cyclin B/cyclin-dependent kinase 1 (CDK1) phosphorylates inhibitor of apoptosis stimulating protein of P53 (iASPP) to promote iASPP nucleus localization and its inhibitory effect on p53. However, p53 is frequently mutated in Burkitt lymphoma, which gains novel oncogenic properties. Recently, the p53 family member, p63, became an attractive gene for the therapeutic strategies for patients with cancer...
August 13, 2018: Journal of Cellular Biochemistry
Leslie Padrnos, Brenda Ernst, Amylou C Dueck, Heidi E Kosiorek, Brenda F Ginos, Angela Toro, Patrick B Johnston, Thomas M Habermann, Jose F Leis, Joseph R Mikhael, Grzegorz S Nowakowski, Joseph Colgan, Luis Porrata, Stephen M Ansell, Thomas E Witzig, Craig Reeder
BACKGROUND: Treatment outcomes have improved in lymphoid malignancies but relapse remains inevitable for most patients. Everolimus and lenalidomide have shown clinical activity as single agents in patients with relapsed and refractory Hodgkin and non-Hodgkin lymphomas. PATIENTS AND METHODS: The present phase I/II trial for patients with relapsed and refractory lymphoid malignancy opened at Mayo Clinic from January 2011 to May 2013. The trial used a standard cohort 3 + 3 design to determine the maximum tolerated dose for the combination...
June 15, 2018: Clinical Lymphoma, Myeloma & Leukemia
Wolfgang Fischbach
BACKGROUND:  Data on colorectal lymphoma in general and on MALT (mucosa-associated-lymphoid tissue) lymphoma, in particular are, very rare. There are no existing recommendations from current guidelines for how to manage these patients. We here report our experience from a clinical series. AIM:  The aim of this study is to present clinical features and the endoscopic appearance of colorectal MALT lymphoma and therapeutic approaches. METHODS:  Seven patients (5 male and 2 female, aged 47 - 75 years) were diagnosed to have colorectal MALT lymphoma...
August 2018: Zeitschrift Für Gastroenterologie
Ryo Sasaki, Yasuyuki Ohta, Yuto Yamada, Koh Tadokoro, Yoshiaki Takahashi, Kota Sato, Jingwei Shang, Mami Takemoto, Nozomi Hishikawa, Toru Yamashita, Takao Yasuhara, Isao Date, Shuntaro Ikegawa, Nobuharu Fujii, Koji Abe
Neurolymphomatosis is a rare form of extranodal malignant lymphoma defined as the infiltration of malignant lymphocytes into the central or peripheral nerve. We herein report a case of neurolymphomatosis in the cauda equina diagnosed by an open surgical biopsy. He presented with muscle weakness, atrophy, numbness and hypoesthesia in the bilateral lower extremities with the accumulation of 18 fluoro-2-deoxyglucose (FDG) in the bilateral cauda equina. Cerebrospinal fluid (CSF) cytology (three times) and flow cytometry (two times) and biopsies of the left sural nerve, bone marrow, paranasal sinus and left testis were all negative for malignancy, so finally we performed a surgical open biopsy of the cauda equina by laminectomy and diagnosed him with diffuse large B-cell lymphoma (DLBCL) in the cauda equina...
August 10, 2018: Internal Medicine
Kaduveettil Gopinathan Gopakumar, Shwetha Seetharam, Jagathnath Krishna Km, Manjusha Nair, Binitha Rajeswari, Guruprasad Cs, Prasanth Vr, Priyakumari Thankamony
BACKGROUND: Data from low- and middle-income countries on tumor lysis syndrome (TLS) in the pediatric population are limited. This study aims to analyze the clinical and biochemical characteristics and treatment outcomes of TLS in children with leukemia/lymphomas in a resource-limited setting. PROCEDURE: Children with intermediate risk (IRD) and high risk (HRD) for developing TLS were retrospectively studied at a tertiary cancer center in India. RESULTS: Over a three-year period, 224 children with acute leukemia/lymphoma having IRD (21...
August 12, 2018: Pediatric Blood & Cancer
M Janaki Ramaiah, S Vaishnave
BMI-1 (B-lymphoma Mo-MLV insertion region 1) is a key protein partner in polycomb repressive complex 1 (PRC1) that helps in maintaining the integrity of the complex. It is also a key player in ubiquitination of histone H2A which affects gene expression pattern involved in various cellular processes such as cell proliferation, growth, DNA repair, apoptosis and senescence. In many cancers, Overexpression of BMI1correlates with advanced stages of disease, aggressive clinicopathological behavior, poor prognosis resistance to radiation and chemotherapy...
August 7, 2018: Gene
Yufu Wang, Jing Li, Rongzhi Wei, Chao Liu, Andrew Nataraj, Jinglong Yan
STUDY DESIGN: Retrospective analysis. OBJECTIVE: To determine the prognostic indicators in patients with bone lymphoma of the spine SUMMARY OF BACKGROUND DATA.: To date, prognosis for patients with spinal bone lymphoma is based on results from small series. Large population-based observational studies are lacking. METHODS: The Surveillance, Epidemiology, and End Results (SEER) Registry was used to identify all patients with bone lymphoma of the spine from 1995 through 2014...
August 9, 2018: Spine
Birte Friedrichs, Matthias Stelljes, Norbert Schmitz
PURPOSE OF REVIEW: T - and natural killer (NK) cell neoplasms are a heterogeneous group of rare diseases with often inferior outcome. Only few studies exist, clarifying the role of allogeneic transplantation in different clinical scenarios. Larger prospective randomized studies are largely missing even for the more frequent entities. Mostly retrospective analysis and anecdotal reports of patients with advanced disease are available, hampering direct conclusions on the significance of allogeneic stem cell transplantation (alloSCT)...
September 2018: Current Opinion in Oncology
Camille Laurent, Corinne Haioun, Pierre Brousset, Philippe Gaulard
PURPOSE OF REVIEW: Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) is a rare form of lymphoma arising adjacent to a breast implant. We aim to review the pathogenesis and clinico-biological features of BI-ALCL. RECENT FINDINGS: BI-ALCL is a new provisional entity in the 2017 updated WHO classification. Among several hypotheses, BI-ALCL development seems to be determined by the interaction of immune response related to implant products and additional genetic events...
September 2018: Current Opinion in Oncology
Savannah Ross, Kristen Eisenman, Kelly W Maloney
Pediatric Burkitt lymphoma has historically been treated with intensive methotrexate-based chemotherapy, which improves patient survival while causing severe toxicities. Young patients typically have better outcomes with intensive therapies, while adults and immunocompromised patients have higher toxicities and worse outcomes. Newer treatment regimens, including etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab (EPOCH-R), show promise for these patients. However, few studies exist to demonstrate efficacy and improved toxicity profile with EPOCH-R...
August 8, 2018: Journal of Pediatric Hematology/oncology
Ruth de Francisco, Andrés Castaño-García, Susana Martínez-González, Isabel Pérez-Martínez, Ana J González-Huerta, Lucía R Morais, María S Fernández-García, Santiago Jiménez, Susana Díaz-Coto, Pablo Flórez-Díez, Adolfo Suárez, Sabino Riestra
BACKGROUND: Little is known about the impact of Epstein-Barr virus (EBV) infection on clinical outcomes in adults with inflammatory bowel disease (IBD). AIM: To evaluate seroprevalence, seroconversion rate and complications associated with EBV infection in an adult IBD cohort attending a tertiary hospital in Spain between 2006 and 2016. METHODS: EBV serological status was performed. In seronegative patients, the seroconversion rate was evaluated...
August 10, 2018: Alimentary Pharmacology & Therapeutics
Hilka Rauert-Wunderlich, Anja Mottok, David W Scott, Lisa M Rimsza, German Ott, Wolfram Klapper, Michael Unterhalt, Hanneke C Kluin-Nelemans, Olivier Hermine, Sylvia Hartmann, Christoph Thorns, Grzegorz Rymkiewicz, Harald Holte, Martin Dreyling, Eva Hoster, Andreas Rosenwald
Mantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki-67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression-based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61%), standard (27%) or high (12%) risk groups with significantly different outcomes...
August 10, 2018: British Journal of Haematology
Kristie A Blum, Frank G Keller, Sharon Castellino, Anh Phan, Christopher R Flowers
Lymphoma incidence and survival in adolescent and young adult (AYA, defined as 15-39 years of age) and adult patients (>39 years) were assessed using Surveillance, Epidemiology, and End Results (SEER) data. From 2000 to 2014, 431 721 lymphoma cases were reported to SEER, 9% in AYA patients. In the AYA group, the highest age-adjusted incidence rate was for classical Hodgkin lymphoma [HL; 3·4 per 100 000 person-years; 95% confidence interval (CI), 3·38-3·49] followed by diffuse large B cell lymphoma (DLBCL; 1·56, 95% CI, 1·53-1·60) and for adults, it was plasma cell neoplasms (14·17, 95% CI, 14·07-14·27), DLBCL (13·86, 95% CI, 13·76-13·96) and chronic lymphocytic leukaemia (CLL; 13·19, 95% CI, 13·09-13·29)...
August 10, 2018: British Journal of Haematology
T N Gibson, S Beeput, J Gaspard, C George, D Gibson, N Jackson, V Leandre-Broome, N Palmer-Mitchell, C Alexis, J Bird-Compton, C Bodkyn, R Boyle, S McLean-Salmon, M Reece-Mills, C Sin Quee-Brown, U Allen, S Weitzman, V Blanchette, S Gupta
BACKGROUND: English-speaking Caribbean (ESC) childhood cancer outcomes are unknown. PROCEDURE: Through the SickKids-Caribbean Initiative (SCI), we established a multicenter childhood cancer database across seven centers in six ESC countries. Data managers entered patient demographics, disease, treatment, and outcome data. Data collection commenced in 2013, with retrospective collection to 2011 and subsequent prospective collection. RESULTS: A total of 367 children were diagnosed between 2011 and 2015 with a median age of 5...
August 9, 2018: Pediatric Blood & Cancer
Julien J Shine, Elie Boghossian, Gabriel Beauchemin, Vasilios W Papanastasiou, Daniel E Borsuk
INTRODUCTION: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare and recently described type of peripheral T-cell lymphoma. Fewer than 550 cases have been reported worldwide. Although BIA-ALCL is usually indolent, early diagnosis and treatment have been shown to improve outcome. CASE DESCRIPTION: This case report describes the management of a 50-year-old healthy Caucasian woman presenting with rapid painful enlargement of the left breast...
August 9, 2018: Aesthetic Plastic Surgery
Rebecca A Luchtel, Surendra Dasari, Naoki Oishi, Martin Bjerregård Pedersen, Guangzhen Hu, Karen L Rech, Rhett P Ketterling, Jagmohan Sidhu, Xueju Wang, Ryohei Katoh, Ahmet Dogan, N Sertac Kip, Julie M Cunningham, Zhifu Sun, Saurabh Baheti, Julie C Porcher, Jonathan W Said, Liuyan Jiang, Stephen Jacques Hamilton-Dutoit, Michael Boe Møller, Peter Nørgaard, N Nora Bennani, Wee-Joo Chng, Gaofeng Huang, Brian K Link, Fabio Facchetti, James R Cerhan, Francesco d'Amore, Stephen M Ansell, Andrew L Feldman
Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas broadly segregated into ALK-positive and ALK-negative types. While ALK-positive ALCLs consistently bear rearrangements of the ALK tyrosine kinase gene, ALK-negative ALCLs are clinically and genetically heterogeneous. About 30% of ALK-negative ALCLs have rearrangements of DUSP22 and have excellent long-term outcomes with standard therapy. To better understand this group of tumors, we evaluated their molecular signature using gene expression profiling...
August 9, 2018: Blood
Fraser Wright, Greg Hapgood, Aravi Loganathan, Nathan Dunn, Shoni Philpot, Julie Moore, Peter Mollee
OBJECTIVE: To evaluate relative survival of patients in Queensland with different lymphoma subtypes; to determine whether outcomes have improved with recent changes in treatment; to evaluate relative survival according to place of residence and socio-economic status. DESIGN: Retrospective population-based study; analysis of data from the Oncology Analysis System, an online reporting tool for cancer incidence and outcomes in Queensland. PARTICIPANTS: Patients over 15 years of age diagnosed with lymphoma in Queensland during 1993-2012...
August 13, 2018: Medical Journal of Australia
Charlott Mörth, Antonios Valachis, Amal Abu Sabaa, Daniel Molin, Max Flogegård, Gunilla Enblad
The standard treatment for diffuse large B cell lymphoma (DLBCL) is rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine (VCR), and prednisone). Maintaining high dose intensity of cytotoxic treatment has been associated with better outcome but little is known about the role of maintaining VCR. This study aimed to answer whether the omission of vincristine due to neurotoxicity affects patient outcome. A Swedish cohort of patients primarily treated with curative intent for DLBCL or high-grade malignant B cell lymphoma was retrospectively analyzed...
August 8, 2018: Annals of Hematology
David P Sellman, W Greg Simpson, Zachary Klaassen, Rita P Jen, John M DiBianco, Lael Reinstatler, Qiang Li, Rabii Madi, Martha K Terris
Introduction: Primary bladder lymphoma (PBL) is rare, representing 0.2% of extranodal lymphoma and less than 1% of all tumors originating in the bladder. Since the initial description of the disease, low-grade mucosa-associated lymphoid tissue (MALT) lymphoma has been reported as the most common subtype while high-grade disease was thought to represent only 20% of the reported cases. Materials and Methods: One hundred and ninety five patients with PBL from the Surveillance, Epidemiology, and End Results (SEER) registry from 1998-2010 were reviewed...
July 2018: Urology Annals
Sofia Garces, Joseph D Khoury, Rashmi Kanagal-Shamanna, Alireza Salem, Sa A Wang, Chi Young Ok, Shimin Hu, Keyur P Patel, Mark J Routbort, Rajyalakshmi Luthra, Guilin Tang, Ellen J Schlette, Carlos E Bueso-Ramos, L Jeffrey Medeiros, Sanam Loghavi
The presence of expanded proliferation centers (PCs) in lymph nodes involved by chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has been associated with adverse clinical outcomes, but the frequency and significance of PCs in bone marrow (BM) remains unclear. The study group included 36 patients with BM involvement by CLL in which PCs were present. We compared this group with 110 randomly selected BM samples involved by CLL without morphologically discernable PCs. Patients with PCs in BM were younger (median age, 53years [range,18-71] versus 58years [range, 31-82]; P=...
August 4, 2018: Human Pathology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"